Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction

European Heart Journal

Volumn 34, Issue 36, 2013, Pages 2839-2849

  Reil, Jan Christian ^a   Hohl, Mathias ^a   Reil, Gert Hinrich ^b   Granzier, Henk L ^c   Kratz, Mario T ^a   Kazakov, Andrey ^a   Fries, Peter ^a   Müller, Andreas ^a   Lenski, Matthias ^a   Custodis, Florian ^a   Gräber, Stefan ^d   Fröhlig, Gerd ^a   Steendijk, Paul ^e   Neuberger, Hans Ruprecht ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b KLINIKUM OLDENBURG   (Germany)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d SAARLAND UNIVERSITY   (Germany)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diastolic dysfunction; Heart rate reduction; HFPEF; Vascular stiffness; Ventricular arterial coupling

Indexed keywords

IVABRADINE; PHOSPHOLAMBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE HYPERTROPHY; ISOLATED HEART; MALE; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION;

DIASTOLIC DYSFUNCTION; HEART RATE REDUCTION; HFPEF; VASCULAR STIFFNESS; VENTRICULAR-ARTERIAL COUPLING;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; AORTA; BENZAZEPINES; BLOOD GLUCOSE; COLLAGEN; DIASTOLE; HEART FAILURE; HEART RATE; HEMODYNAMICS; INSULIN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICE; MICE, INBRED C57BL; PROTEIN KINASES; RNA, MESSENGER; STROKE VOLUME; SYSTOLE; VASCULAR STIFFNESS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84884867961     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs218     Document Type: Article

References (36)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
2. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
3. Takeda Y, Sakata Y, Mano T, Ohtani T, Kamimura D, Tamaki S, Omori Y, Tsukamoto Y, Aizawa Y, Komuro I, Yamamoto K. Competing risks for heart failure with preserved ejection fraction in diabetic patients. Eur J Heart Fail 2011; 13: 664-669.
4. Kindermann M, Reil JC, Pieske B, von Veldhuisen DJ, Bohm M. Heart failure with normal left ventricular ejection fraction: what is the evidence? Trends Cardiovasc Med 2008; 18: 280-292.
5. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
6. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschope C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008; 117: 2051-2060.
7. Hay I, Rich J, Ferber P, Burkhoff D, Maurer MS. Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol 2005; 288: H1203-H1208.
8. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714-720.
9. Reil JC, Reil GH, Bohm M. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. Trends Cardiovasc Med 2009; 19: 152-157.
10. Colin P, Ghaleh B, Hittinger l, Monnet X, Slama M, Giudicelli JF, Berdeaux A. Differential effects of heart rate reduction and beta blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 2002; 282: H672-H679.
11. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, Kass DA. Effective arterial elastance as index of arterial vascular load in humans. Circulation 1992; 86: 513-521.
12. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial modulator on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994; 112: 37-42.
13. Monnet X, Ghaleh B, Colin P, Hittinger L, Berdeaux A. Effects of heart rate reduction with Ivabradine on exercise induced myocardial ischemia and stunning. J Pharmacol Exp Ther 2001; 299: 1133-1139.
14. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996; 118: 1051-1057.
15. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006; 55: 466-473.
16. Hundley WG, Kitzman DW, Morgan TM, Hamilton CA, Darty SN, Stewart KP, Herrington DM, Link KM, Little WC. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001; 38: 796-802.
17. Reil JC, Hohl M, Oberhofer M, Kazakov A, Kaestner L, Mueller P, Adam O, Maack C, Lipp P, Mewis C, Allessie M, Laufs U, Bohm M, Neuberger HR. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling. Cardiovas Res 2010; 87: 485-493.
18. Borlaug BA, Lam CSP, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease. J Am Coll Cardiol 2009; 54: 410-418.
19. Lahmers S, Wu Y, Call DR, Labeit S, Granzier H. Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. Circ Res 2004; 94: 505-513.
20. ChenC-H, NakayamaM, Nevo E, Fetics BJ, MaughamWL, Kass DA.Coupled systolicventricular and vascular stiffening with age. J AmColl Cardiol 1998; 32: 1221-1227.
21. Kass DA. Ventricular-arterial stiffening: intergrating the pathophysiology. Hypertension 2005; 46: 185-193.
22. Kass DA, Maughan WL. From Emax to pressure-volume relations: a broader view. Circulation 1988; 77: 1203-1212.
23. Baan J, van der Velde ET. Sensitivity of left ventricular end-systolic pressure-volume relation to type of loading intervention in dogs. Circ Res 1988; 62: 1247-1258.
24. Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation 1998; 98: 242-248.
25. Yamakawa H, Takeushi M, Takaoka H, Hata K, Mori M, Yokoyama M. Negative chronotropic effect of ß-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work. Circulation 1996; 94: 340-345.
26. Kass DA, Marino P, Maughan WL, Sagawa K. Determinants of end-systolic pressure-volume relations during acute regional ischemia in situ. Circulation 1989; 80: 1783-1794.
27. Ciobotaru V, Heimburger M, Louedec L, Heymes C, Ventura-Clapier R, Bedossa P, Escoubet B, Michel JB, Mercadier JJ, Logeart D. Effect of long-term heart rate reduction by If current inhibition on pressure overload-induced heart failure in rats. J Pharm Exp Ther 2008; 324: 43-49.
28. Nielsen JM, Kristiansen SB, Nørregaard R, Nørregaard R, Andersen CL, Denner L, Nielsen TT, Flyvbjerg A, Bøtker HE. Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail 2009; 11: 638-647.
29. van Heerebeek L, Borbe'ly A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113: 1966-1973.
30. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefication. J Clin Invest 2006; 116: 1547-1560.
31. Chung CS, Granzier HL. Contribution of titin and extracellular matrix to passive pressure and measurement of sarcomere length in the mouse left ventricle. J Mol Cell Cardiol 2011; 50: 731-739.
32. Granzier HL, Labeit S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ Res 2004; 94: 284-295.
33. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbe'ly A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550.
34. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000; 32: 2131-2139.
35. Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas P, Bohm M, Dei Cas L. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012; 14: 219-225.
36. Nodari S, Metra M, Dei Cas L. B-Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolo. Eur J Heart Fail 2003; 5: 621-627.